skip to main content
OSTI.GOV title logo U.S. Department of Energy
Office of Scientific and Technical Information

Title: Delivering CRISPR: a review of the challenges and approaches

Abstract

Gene therapy has long held promise to correct a variety of human diseases and defects. Discovery of the Clustered Regularly-Interspaced Short Palindromic Repeats (CRISPR), the mechanism of the CRISPR-based prokaryotic adaptive immune system (CRISPR-associated system, Cas), and its repurposing into a potent gene editing tool has revolutionized the field of molecular biology and generated excitement for new and improved gene therapies. Additionally, the simplicity and flexibility of the CRISPR/Cas9 site-specific nuclease system has led to its widespread use in many biological research areas including development of model cell lines, discovering mechanisms of disease, identifying disease targets, development of transgene animals and plants, and transcriptional modulation. In this review, we present the brief history and basic mechanisms of the CRISPR/Cas9 system and its predecessors (ZFNs and TALENs), lessons learned from past human gene therapy efforts, and recent modifications of CRISPR/Cas9 to provide functions beyond gene editing. We introduce several factors that influence CRISPR/Cas9 efficacy which must be addressed before effective in vivo human gene therapy can be realized. The focus then turns to the most difficult barrier to potential in vivo use of CRISPR/Cas9, delivery. We detail the various cargos and delivery vehicles reported for CRISPR/Cas9, including physical delivery methods (e.g.more » microinjection; electroporation), viral delivery methods (e.g. adeno-associated virus (AAV); full-sized adenovirus and lentivirus), and non-viral delivery methods (e.g. liposomes; polyplexes; gold particles), and discuss their relative merits. We also examine several technologies that, while not currently reported for CRISPR/Cas9 delivery, appear to have promise in this field. The therapeutic potential of CRISPR/Cas9 is vast and will only increase as the technology and its delivery improves.« less

Authors:
 [1];  [1];  [1]; ORCiD logo [1]
  1. Sandia National Lab. (SNL-NM), Albuquerque, NM (United States). Bioenergy and Defense Technologies
Publication Date:
Research Org.:
Sandia National Lab. (SNL-NM), Albuquerque, NM (United States)
Sponsoring Org.:
USDOE National Nuclear Security Administration (NNSA); SNL Laboratory Directed Research and Development (LDRD) Program
OSTI Identifier:
1483332
Alternate Identifier(s):
OSTI ID: 1474089
Report Number(s):
SAND-2018-10248J
Journal ID: ISSN 1071-7544; 667983
Grant/Contract Number:  
NA0003525
Resource Type:
Journal Article: Published Article
Journal Name:
Drug Delivery
Additional Journal Information:
Journal Volume: 25; Journal Issue: 1; Journal ID: ISSN 1071-7544
Publisher:
Taylor & Francis
Country of Publication:
United States
Language:
English
Subject:
60 APPLIED LIFE SCIENCES; CRISPR; Cas9; history; overview; review; drug delivery; prospective

Citation Formats

Lino, Christopher A., Harper, Jason C., Carney, James P., and Timlin, Jerilyn A. Delivering CRISPR: a review of the challenges and approaches. United States: N. p., 2018. Web. doi:10.1080/10717544.2018.1474964.
Lino, Christopher A., Harper, Jason C., Carney, James P., & Timlin, Jerilyn A. Delivering CRISPR: a review of the challenges and approaches. United States. doi:10.1080/10717544.2018.1474964.
Lino, Christopher A., Harper, Jason C., Carney, James P., and Timlin, Jerilyn A. Fri . "Delivering CRISPR: a review of the challenges and approaches". United States. doi:10.1080/10717544.2018.1474964.
@article{osti_1483332,
title = {Delivering CRISPR: a review of the challenges and approaches},
author = {Lino, Christopher A. and Harper, Jason C. and Carney, James P. and Timlin, Jerilyn A.},
abstractNote = {Gene therapy has long held promise to correct a variety of human diseases and defects. Discovery of the Clustered Regularly-Interspaced Short Palindromic Repeats (CRISPR), the mechanism of the CRISPR-based prokaryotic adaptive immune system (CRISPR-associated system, Cas), and its repurposing into a potent gene editing tool has revolutionized the field of molecular biology and generated excitement for new and improved gene therapies. Additionally, the simplicity and flexibility of the CRISPR/Cas9 site-specific nuclease system has led to its widespread use in many biological research areas including development of model cell lines, discovering mechanisms of disease, identifying disease targets, development of transgene animals and plants, and transcriptional modulation. In this review, we present the brief history and basic mechanisms of the CRISPR/Cas9 system and its predecessors (ZFNs and TALENs), lessons learned from past human gene therapy efforts, and recent modifications of CRISPR/Cas9 to provide functions beyond gene editing. We introduce several factors that influence CRISPR/Cas9 efficacy which must be addressed before effective in vivo human gene therapy can be realized. The focus then turns to the most difficult barrier to potential in vivo use of CRISPR/Cas9, delivery. We detail the various cargos and delivery vehicles reported for CRISPR/Cas9, including physical delivery methods (e.g. microinjection; electroporation), viral delivery methods (e.g. adeno-associated virus (AAV); full-sized adenovirus and lentivirus), and non-viral delivery methods (e.g. liposomes; polyplexes; gold particles), and discuss their relative merits. We also examine several technologies that, while not currently reported for CRISPR/Cas9 delivery, appear to have promise in this field. The therapeutic potential of CRISPR/Cas9 is vast and will only increase as the technology and its delivery improves.},
doi = {10.1080/10717544.2018.1474964},
journal = {Drug Delivery},
number = 1,
volume = 25,
place = {United States},
year = {Fri May 25 00:00:00 EDT 2018},
month = {Fri May 25 00:00:00 EDT 2018}
}

Journal Article:
Free Publicly Available Full Text
Publisher's Version of Record at 10.1080/10717544.2018.1474964

Citation Metrics:
Cited by: 5 works
Citation information provided by
Web of Science

Save / Share:

Works referenced in this record:

Saturation editing of genomic regions by multiplex homology-directed repair
journal, September 2014

  • Findlay, Gregory M.; Boyle, Evan A.; Hause, Ronald J.
  • Nature, Vol. 513, Issue 7516, p. 120-123
  • DOI: 10.1038/nature13695

Repurposing CRISPR as an RNA-Guided Platform for Sequence-Specific Control of Gene Expression
journal, February 2013


Genome-Scale CRISPR-Cas9 Knockout Screening in Human Cells
journal, December 2013

  • Shalem, Ophir; Sanjana, Neville E.; Hartenian, Ella
  • Science, Vol. 343, Issue 6166, p. 84-87
  • DOI: 10.1126/science.1247005

A Programmable Dual-RNA-Guided DNA Endonuclease in Adaptive Bacterial Immunity
journal, June 2012


Multiplex Genome Engineering Using CRISPR/Cas Systems
journal, January 2013


Double Nicking by RNA-Guided CRISPR Cas9 for Enhanced Genome Editing Specificity
journal, September 2013


Porous Nanoparticle Supported Lipid Bilayers (Protocells) as Delivery Vehicles
journal, February 2009

  • Liu, Juewen; Stace-Naughton, Alison; Jiang, Xingmao
  • Journal of the American Chemical Society, Vol. 131, Issue 4, p. 1354-1355
  • DOI: 10.1021/ja808018y

One-Step Generation of Mice Carrying Mutations in Multiple Genes by CRISPR/Cas-Mediated Genome Engineering
journal, May 2013


RNA-Guided Human Genome Engineering via Cas9
journal, January 2013


RNA-guided editing of bacterial genomes using CRISPR-Cas systems
journal, January 2013

  • Jiang, Wenyan; Bikard, David; Cox, David
  • Nature Biotechnology, Vol. 31, Issue 3, p. 233-239
  • DOI: 10.1038/nbt.2508

An updated evolutionary classification of CRISPR�Cas systems
journal, September 2015

  • Makarova, Kira S.; Wolf, Yuri I.; Alkhnbashi, Omer S.
  • Nature Reviews Microbiology, Vol. 13, Issue 11, p. 722-736
  • DOI: 10.1038/nrmicro3569

Small CRISPR RNAs Guide Antiviral Defense in Prokaryotes
journal, August 2008

  • Brouns, S. J. J.; Jore, M. M.; Lundgren, M.
  • Science, Vol. 321, Issue 5891, p. 960-964
  • DOI: 10.1126/science.1159689

Discovery and Functional Characterization of Diverse Class 2 CRISPR-Cas Systems
journal, November 2015


DNA targeting specificity of RNA-guided Cas9 nucleases
journal, July 2013

  • Hsu, Patrick D.; Scott, David A.; Weinstein, Joshua A.
  • Nature Biotechnology, Vol. 31, Issue 9, p. 827-832
  • DOI: 10.1038/nbt.2647

Increasing the efficiency of precise genome editing with CRISPR-Cas9 by inhibition of nonhomologous end joining
journal, March 2015

  • Maruyama, Takeshi; Dougan, Stephanie K.; Truttmann, Matthias C.
  • Nature Biotechnology, Vol. 33, Issue 5, p. 538-542
  • DOI: 10.1038/nbt.3190

Evolution and classification of the CRISPR�Cas systems
journal, May 2011

  • Makarova, Kira S.; Haft, Daniel H.; Barrangou, Rodolphe
  • Nature Reviews Microbiology, Vol. 9, Issue 6, p. 467-477
  • DOI: 10.1038/nrmicro2577